Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
arcticnovartis
- Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented
- Biomarker data informing use of investigational CAR-T cell therapy rapcabtagene autoleucel (YTB323) in systemic lupus erythematosus also to be presented
- Data underscore Novartis commitment to advance innovative medicines for complex, difficult-to-treat autoimmune diseases with high unmet need